WASHINGTON, Sept. 2 /PRNewswire/ -- The law firm of Finkelstein, Thompson & Loughran announces that a lawsuit seeking class action status has been filed in the United States District Court for the Northern District of Georgia against Immucor, Inc. (NASDAQ:BLUDE) ("Immucor" or the "Company") on behalf of persons who purchased Immucor common stock between January 7, 2005 through and including August 29, 2005 ("Class Period"). Finkelstein, Thompson & Loughran is investigating similar claims at this time and welcomes inquiries from potential class members concerning their rights and interests in this matter. The lawsuit alleges that Immucor violated federal securities laws by issuing false or misleading public statements. Specifically, the complaint alleges Immucor and various officers of Immucor, throughout the class period, misrepresented that Immucor's financial statements and disclosures fairly and accurately represented Immucor's results of operations as required by Generally Accepted Accounting Principles ("GAAP") and the Exchange Act. On August 26, 2005 Immucor announced that the Securities and Exchange Commission (the "SEC") had launched a formal investigation into payments made by its Italian unit and its president, Defendant De Chirico, in October 2003 to a physician connected with a hospital with which the Company was doing business. After the market closed on August 29, 2005, the Company revealed further that it would be revising its previously issued results for at least two quarters in order to account for a previously unrecorded accrued bonus, that its Form 10-K for fiscal year 2005 would be further delayed, and that its Chief Financial Officer had resigned. In response to this information, the price of Immucor common stock dropped from a closing price of $28.61 on August 25, 2005 to close at $24.00 per share on August 30, 2005 -- a dramatic drop of 16%. If you are a member of the class, you may, no later than October 17, 2005, request that the Court appoint you as a lead plaintiff. A lead plaintiff is a class member appointed by the Court to direct the litigation on behalf of the class. Although a class member need not be appointed as a lead plaintiff to receive a proportionate share of any proceeds of the litigation, lead plaintiffs make important decisions that could affect the prosecution of the class claims, including decisions concerning settlement. The securities laws create a rebuttable presumption that the plaintiff with the largest financial interest in the litigation is the most adequate to serve as a lead plaintiff. With offices in Washington, DC and San Francisco, CA, Finkelstein, Thompson & Loughran has spent almost three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, in the past ten years, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. If you have any questions concerning this press release or your rights or interests, please contact Finkelstein, Thompson & Loughran's Washington, DC office at (877) 337-1050, or by email at . DATASOURCE: Finkelstein, Thompson & Loughran CONTACT: Donald J. Enright, Esq. of Finkelstein, Thompson & Loughran, +1-202-337-8000 Web site: http://www.ftllaw.com/

Copyright